Deborah Saraggi

Deborah Saraggi

Auto-generated profile, based on publicly available information

Deborah Saraggi

Department of Medicine (DIMED), University of Padua, Padua, PD, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
DSDeborah Saraggi
Deborah Saraggi
Matteo FassanMatteo Fassan
Matteo Fassan
CMClaudia Mescoli
Claudia Mescoli
MSMarco Scarpa
Marco Scarpa
NVNicola Valeri
Nicola Valeri
MRMassimo Rugge
Massimo Rugge

17 April 2017 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
VMVeronica Martini
Veronica Martini
CGCristina Gattazzo
Cristina Gattazzo
FFFederica Frezzato
Federica Frezzato
VTValentina Trimarco
Valentina Trimarco
MPMarco Pizzi
Marco Pizzi
LTLIVIO TRENTIN
LIVIO TRENTIN
Summary: Cortactin (CTTN) is a substrate of the Src kinase Lyn that is known to play an actin cytoskeletal regulatory role involved in cell migration and cancer progression following its phosphorylation at Y421. We recently demonstrated that Cortactin is overexpressed in patients with chronic lymphocytic leukaemia (CLL). This work was aimed at defining the functional role of Cortactin in these patients. We found that Cortactin is variably expressed in CLL patients both in the peripheral blood and lymph nodes and that its expression correlates with the release of matrix metalloproteinase 9 (MMP‐9) and the motility of neoplastic cells. Cortactin knockdown, by siRNA, induced a reduction in MMP‐9 release as well as a decrease of migration capability of leukaemic B cells in vitro, also after chemotactic stimulus. Furthermore, Cortactin phosphorylation was lowered by the Src kinase‐inhibitor PP2 with a consequent decrease of MMP‐9 release in culture medium. An impaired migration, as compared to control experiments without Cortactin knockdown, was observed following CXCL12 triggering. Reduced Cortactin expression and phosphorylation were also detected both in vivo and in vitro after treatment with Ibrutinib, a Btk inhibitor. Our results highlight the role of Cortactin in CLL as a check‐point molecule between the BCR and CXCR4 signalling pathways.

29 June 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
DSDeborah Saraggi
Deborah Saraggi
FGFrancesca Galuppini
Francesca Galuppini
Andrea remoAndrea remo
Andrea remo
EUEmanuele D L Urso
Emanuele D L Urso
DBDeborah Bacchin
Deborah Bacchin
MRMassimo Rugge
Massimo Rugge

26 February 2017 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
Matteo FassanMatteo Fassan
Matteo Fassan
DSDeborah Saraggi
Deborah Saraggi
LBLaura Balsamo
Laura Balsamo
SRStefano Realdon
Stefano Realdon
MSMarco Scarpa
Marco Scarpa
MRMassimo Rugge
Massimo Rugge
Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P < .001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P < .001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.

17 December 2015 in Oncotarget
Verified
Journal Article
Open access
Matteo FassanMatteo Fassan
Matteo Fassan
DSDeborah Saraggi
Deborah Saraggi
LBLaura Balsamo
Laura Balsamo
Luciano CascioneLuciano Cascione
Luciano Cascione
CCCarlo Castoro
Carlo Castoro
MRMassimo Rugge
Massimo Rugge
Let-7c down-regulation in Helicobacter pylori -related gastric carcinogenesis Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis

1 April 2014 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
MPMarco Pizzi
Marco Pizzi
DSDeborah Saraggi
Deborah Saraggi
Matteo FassanMatteo Fassan
Matteo Fassan
FMFrancis Megraud
Francis Megraud
FMFrancesco Di Mario
Francesco Di Mario
MRMassimo Rugge
Massimo Rugge
Irrespective of its etiology, long-standing, non-self-limiting gastric inflammation (mostly in Helicobacter pylori-associated cases) is the cancerization ground on which epidemic (intestinal-type) gastric carcinoma (GC) can develop. The natural history of invasive gastric adenocarcinoma encompasses gastritis, atrophic mucosal changes, and intraepithelial neoplasia (IEN). The topography, the extent and the severity of the atrophic changes significantly correlate with the risk of developing both IEN and GC. In recent years, both noninvasive (serological) tests and invasive (endoscopy/biopsy) procedures have been proposed to stratify patients according to different classes of GC risk. As a consequence, different patient-tailored GC secondary prevention strategies have been put forward. This review summarizes the histological features of H. pylori-related gastritis and the natural history of the disease. Histological and serological strategies to assess GC risk as well as the clinical management of atrophic gastritis patients are also discussed.